Omis

Quick links to important sections

Omis

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Omis

Property Description
Active ingredient Omeprazole
Form Delayed-release capsule/tablet; preparation for injection
Pharmacological class Proton-pump inhibitor (PPI)
Common use Suppression of gastric acid secretion
Origin Synthetic organic compound

What Type of Drug is Omis?

Omis is a commercial name for a medicine containing the active ingredient Omeprazole, a synthetic compound that belongs to the Proton-pump inhibitor (PPI) class. The drug is chemically classified as a Substituted benzimidazole. The classification as a PPI is clinically recognized for defining the function of Omis as a powerful antisecretory class of compounds designed to control acid levels in the digestive system. Omis is typically supplied as a single-ingredient product, focusing solely on the action of Omeprazole.

Composition and Pharmaceutical Forms

The core of Omis's therapeutic effect is its active ingredient, Omeprazole. Since the Omeprazole molecule is acid-labile (easily destroyed by stomach acid), it is administered as an inactive prodrug via specialized forms, such as the delayed-release capsule or the delayed-release tablet, to protect the drug from degradation. Omeprazole's chemical nature necessitates this specialized delayed-release formulation to ensure efficacy. These oral forms feature enteric-coated granules designed to bypass the stomach's acid, ensuring the active component reaches the small intestine for absorption. Preparations for injection into a vein are also available for use in medical settings.

Omis's General Purpose as an Antisecretory Agent

The general purpose of Omis is to provide powerful and sustained suppression of gastric basal and stimulated acid secretion. This is achieved through the drug’s highly selective mechanism: it works by irreversibly deactivating the specific Hydrogen-potassium ATPase pumps in the stomach lining that are responsible for manufacturing acid. This long-lasting inhibitory effect on the proton pump is the cornerstone of the drug's clinical efficacy. Functioning as an antisecretory agent, Omis reduces the overall volume of acid, which is typically used to manage conditions where controlling stomach acidity is critical. This action helps to alleviate general discomfort associated with excess acidity and facilitates a healing environment for the digestive lining.

Regulatory References

  1. StatPearls, NIH

What side effects are possible with Omis?

Possible Side Effects and Safety Information

The officially documented safety profile for Omis, which contains mathbfOmeprazole, classifies adverse reactions by frequency and the body system affected, consistent with global regulatory standards.


Classification of Documented Adverse Reactions

Adverse effects are grouped by their reported frequency in official prescribing information:

  • Common Reactions (ge 1/100 to < 1/10): These frequently reported effects primarily involve the gastrointestinal and nervous systems, including mathbfheadache, mathbfabdominal pain, mathbfconstipation, mathbfdiarrhea, mathbfflatulence, and mathbfnausea/vomiting.
  • Uncommon Reactions (ge 1/1,000 to < 1/100): Effects such as mathbfdizziness, mathbfsomnolence, mathbfinsomnia, and dermatological reactions like mathbfrash and mathbfurticaria are listed in this category.

Serious Adverse Reactions and Safety Constraints

The regulatory label documents rare but clinically significant events. These mathbfSerious Adverse Reactions include severe cutaneous reactions like mathbfStevens-Johnson syndrome and mathbfToxic Epidermal Necrolysis, as well as severe blood disorders like mathbfagranulocytosis and mathbfpancytopenia. The drug is mathbfcontraindicated in individuals with known hypersensitivity to the substituted mathbfbenzimidazole drug class.


Time-Related and Population-Specific Safety Patterns

Official safety information highlights that mathbflong-term use (typically exceeding one year) is associated with an increased risk of mathbfbone fracture (hip, wrist, spine) and mathbfhypomagnesemia. For specific populations, notes are provided for patients with mathbfsevere hepatic impairment due to increased drug exposure, and older adults are noted to have an increased risk of bone fracture associated with long-term use.

Overdose and Emergency Response

Omis Overdose and when to seek help

The information below summarizes the officially documented descriptions of Omis (Omeprazole) overdose as detailed in governmental regulatory sources, such as the FDA Prescribing Information and the Summary of Product Characteristics (SmPC).

Omeprazole overdose is generally characterized by a cluster of non-severe and transient clinical features. Documented manifestations may include nausea, vomiting, abdominal pain, diarrhea, headache, dizziness, confusion, and somnolence (drowsiness). In some high-dose exposures, regulatory reports have cited events such as tachycardia (fast heart rate) and flushing.

Required Emergency Actions

The official labeling mandates that no specific antidote for omeprazole overdosage is known. Due to this constraint, the required clinical management involves symptomatic and supportive treatment provided in a medical setting.

Regulators instruct patients and caregivers to seek immediate medical attention or contact a Poison Control Center right away in the event of a suspected overdose. The drug is extensively protein bound, meaning procedures like dialysis are not expected to be effective for substance removal.

Therapeutic Uses of Omis

What Omis treats: main uses and benefits

Omis is primarily used to address conditions associated with excess gastric acid and supports relief across several key symptomatic domains.

The medication is commonly used for managing conditions presenting with systemic or localized discomfort, such as Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis (EE), where patients experience frequent heartburn and distressing acid regurgitation. It also supports the healing of active duodenal and gastric ulcers. Additionally, it is applied in combination therapy to address H. pylori bacteria and is relevant for managing Pathologic Hypersecretory Conditions, such as Zollinger-Ellison syndrome.

“Omis supports the patient during difficult episodes by easing distress related to acid-induced pain and discomfort.”

Its therapeutic effect contributes to reducing the risk of ulcer recurrence and provides supportive relief for stress ulcer prophylaxis in acute hospital settings. The therapeutic effect contributes to maintaining a sense of stability when symptoms are more noticeable, assisting with functional stability during symptomatic periods.


Quick Fact: Support for Acid-Related Pain Omis addresses symptoms related to inflammatory or irritative states, contributing to the easing of discomfort arising from active tissue damage in the stomach and esophagus.

Eligibility and Restrictions for Use

Who Can and Cannot Use Omis?

Eligibility for Omis (Omeprazole) is determined by official regulatory bodies, defining patient populations that are approved, restricted, or excluded from use.


Contraindicated Populations

Use of Omis is absolutely contraindicated in patients with a history of hypersensitivity to Omeprazole, to any other substituted benzimidazole compound (the drug class), or to any component in the formulation. Additionally, Omis must not be used concurrently with products containing Rilpivirine, a medication used for treating HIV.

Age-Based and Conditional Eligibility

Age-Related Rules:

Population Regulatory Status
Adults Generally eligible for all labeled indications.
Pediatrics (Ages 1–16) Eligible for symptomatic GERD and Erosive Esophagitis.
Infants (<1 Year) Use is not recommended.
Pediatric Limitations Safety and effectiveness for H. pylori eradication and duodenal ulcers is not established.

Special Considerations:

  • Severe Hepatic Impairment: Requires restricted use, and a dose adjustment should be considered due to altered drug metabolism.
  • Pregnancy and Lactation: Use during pregnancy requires a formal benefit-versus-risk assessment. For breastfeeding mothers, the decision is made to discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns of Omis (Omeprazole) as established by government regulatory bodies.

Category Detail (Strictly from Regulatory Documents)
Medicinal product categories with documented interactions CYP2C19 substrates; Medicines dependent on gastric pH for absorption; CYP2C19 and CYP3A4 inhibitors/inducers.
Interaction-related restrictions Co-administration with Nelfinavir is a contraindicated combination due to the severe reduction in Nelfinavir plasma concentrations. Avoid co-administration with St. John's Wort due to decreased Omeprazole exposure.

Official interaction statements

Official interaction statements detail two main pharmacokinetic mechanisms. Omeprazole is documented as a moderate CYP2C19 inhibitor, which may lead to increased systemic exposure of co-administered CYP2C19 substrates such as Cilostazol, Diazepam, and Phenytoin. Conversely, this inhibition reduces the formation of Clopidogrel's active metabolite, diminishing its anti-platelet effect. The medication also causes a sustained increase in intragastric pH, a pharmacodynamic effect that reduces the solubility and absorption of drugs requiring an acidic environment, including the antiretrovirals Atazanavir and Rilpivirine, as well as Ketoconazole and Iron salts. Substances that inhibit or induce the metabolizing enzymes, such as Voriconazole or Rifampin, can also alter the Omeprazole plasma levels. A specific note exists for patients with hepatic impairment, where Omeprazole clearance is reduced, increasing its systemic exposure.

Connection to the overall interaction profile

Regulatory documents define the Omis interaction structure primarily through two distinct mechanisms: pharmacokinetic inhibition of the CYP2C19 enzyme and pharmacodynamic effects resulting from sustained pH elevation within the stomach. These documented effects result in formal restrictions, including a stated contraindicated combination and required consideration of altered exposure for a range of co-administered medicinal products, as classified by government health authorities.

Mechanism of Action

How Omis Works: Mechanism of Action

Omis (Omeprazole) is a drug that works by selectively inhibiting the production of acid in the stomach. Its action is defined by a two-step cascade that results in sustained enzyme inactivation.


Direct Inhibition of the Proton Pump

The drug's primary biological target is the H⁺/K⁺-ATPase enzyme system, or Proton Pump, found in the gastric parietal cells. Omis acts as an irreversible inhibitor only after it is activated within the acidic environment of the cell's canaliculi. It binds permanently to the pump, thereby blocking the final step of acid secretion and resulting in a reduction in the overall acid output.


Sustained Mechanistic Effect via Covalent Binding

This binding involves the formation of a covalent bond with the Proton Pump protein. This molecular action leads to a prolonged duration of acid-blocking effect, as acid production only resumes when the body synthesizes new H⁺/K⁺-ATPase enzyme units. The consequence is an elevation of the gastric pH (lower acidity), which triggers a predictable, compensatory rise in the hormone gastrin as part of the body's homeostatic feedback loop.

Dosage and Administration Information

How to use Omis

Omis (Omeprazole) is administered through two primary, officially approved routes: oral via delayed-release forms (capsules, tablets, or suspension) and intravenous (IV) injection or infusion, which is reserved for use in clinical settings. The oral forms are specifically designed as delayed-release because the active ingredient is highly susceptible to degradation by stomach acid. To ensure efficacy, the official instructions mandate that the capsule or tablet must be swallowed whole and not chewed, crushed, or split, thereby preserving the integrity of the enteric coating. If a patient is unable to swallow the capsule, the pellets inside may be mixed with applesauce and swallowed immediately without chewing.

The dosing schedule is regimen-specific, based on the condition being addressed. For standard acute conditions, the typical adult dose is 20 mg or 40 mg, taken once daily. In contrast, regimens for H. pylori eradication require the 20 mg dose to be taken twice daily as part of a combination therapy. Regardless of frequency, the dose should be taken before a meal, preferably in the morning. Treatment for conditions like active ulcers or erosive esophagitis is generally a short course, often lasting four to eight weeks. However, treatment for Pathological Hypersecretory Conditions often requires a divided dose and may be administered long-term, with high daily doses up to 360 mg. Minor dose reduction is stipulated for patients with severe hepatic impairment, while pediatric dosing is weight-based.

Recent Clinical Evidence

Research evidence / Overview of Studies for Omis


Evidence for Use in Symptomatic Reflux and Erosive Esophagitis

Research exploring the use of Omis in studies focused on Gastroesophageal Reflux Disease (GERD) and research tracking the healing of the digestive lining in Erosive Esophagitis (EE) primarily comes from Randomized Controlled Trials (RCTs) and comprehensive reviews of these trials. These studies were designed to examine how Omis compares to a placebo or to other types of acid-reducing medicines. For symptomatic GERD, research examined outcomes related to physical discomfort, specifically how the frequency and intensity of symptoms like heartburn and acid regurgitation evolved over time. For EE, the primary focus of studies was on monitoring endoscopic healing rates—that is, the successful resolution of tissue damage in the esophagus—over a short-term period, typically 4 to 8 weeks.

The findings from these controlled studies describe patterns related to measured symptom change during the short-term treatment phases. Studies monitored changes measured during the study period related to how patients reported their experience and overall Quality of Life (QoL). When comparing Omis to other acid-reducing agents, systematic reviews have described consistency in reported outcomes related to healing and short-term symptom change.

Evidence for Ulcer Healing

Omis was studied for use in research focused on both active duodenal ulcers and active benign gastric ulcers. The core research for these conditions utilized short-term RCTs where Omis was compared to placebo and older types of acid suppressants. These trials primarily focused on endoscopic healing rates, which monitored the successful closure of the ulcer crater, usually assessed at 4-week intervals. Data show patterns related to ulcer healing within the defined short-term period of 4 to 8 weeks in the observed populations. Research describes similar findings for healing when Omis was compared to H2-receptor antagonists.

What is Still Uncertain or Under Research

The existing research provides context but also highlights areas where more data is needed. The evidence for H. pylori eradication is influenced by growing concerns regarding antibiotic resistance, which may be associated with variable eradication rates reported in certain populations. Furthermore, while the short-term patterns of symptom change are well-documented, the follow-up durations were limited in many studies, meaning that long-term effects are not fully established. Comparative evidence against newer medicines in this class may be lacking or show mixed findings.

Frequently Asked Questions (FAQ)

Common questions about Omis (FAQ)

Q: How is Omis different from other commonly prescribed medicines for the same condition?

A: Official documents describe Omis as an irreversible inhibitor of the proton pump, which is the enzyme system responsible for creating stomach acid. The drug works by irreversibly inhibiting the proton pumps in the stomach lining. This action provides a prolonged acid-reducing effect, lasting until the body naturally produces new pumps.


Q: What signs or symptoms indicate a possible severe allergic reaction to Omis?

A: Severe hypersensitivity reactions are rare but possible. The official product information states that signs of a severe allergic reaction, such as swelling of the face, tongue, or throat or difficulty breathing, require immediate attention.


Q: Are there any food products, specific diets, or beverages to avoid while taking Omis?

A: Official regulatory documents state that Omis should be taken before a meal. There are no specific restrictions mandated against major food groups or beverages. The official label specifies a method for administration if swallowing the intact capsule is not possible. For detailed use instructions, consult the 'How to Use Omis' section.


Q: How long does it typically take for a person to notice the intended benefits of Omis?

A: Symptomatic relief of acid-related issues like heartburn is often observed within 24 hours of starting treatment. Official data indicates that the drug’s maximum acid-suppressing effect is generally reached after four days of continuous daily use.


Q: What should a person expect the drug to feel like when it is working effectively?

A: The drug's action is primarily noted through a reduction in the frequency and intensity of acid-related symptoms in the digestive tract, such as heartburn and acid regurgitation. This reflects the intended effect of the drug to reduce stomach acid levels.


Q: If Omis doesn't seem to be working right away, does that mean it's ineffective for that person?

A: Due to its mechanism of action, the drug's full effect is typically not immediate after the first dose. Because of how the drug works to inhibit acid production, the maximum acid-suppressing effect is generally reached only after several days of continuous use.


Q: Is there official guidance on when or how to stop Omis treatment after a successful course?

A: Regulatory guidance emphasizes that treatment with Omis should be for the shortest duration necessary to address the condition. For acute conditions, this commonly ranges from four to eight weeks of treatment.


Q: What are the general guidelines for using Omis in people with pre-existing kidney or liver issues?

A: For patients with severe hepatic impairment (liver issues), the official labeling stipulates that a dose reduction should be considered due to the drug’s altered metabolism. However, no dose adjustment is typically required for patients with impaired kidney (renal) function.


Q: Is Omis generally considered appropriate for use in the elderly population?

A: Clinical studies generally indicated no overall differences in the effectiveness or safety profile between older adults and younger patients. However, official safety information notes that long-term use (typically over one year) in older adults is associated with an increased risk of bone fracture.


Q: Does the manufacturer's official labeling for Omis include any known allergens or inactive ingredients of note?

A: Yes, the official package insert includes a full list of all inactive ingredients (also called excipients) used in the formulation. Hypersensitivity to the active ingredient or any of these other components is a condition where the drug is not recommended for use, as noted in the label.


Q: Does Omis commonly cause changes in weight (gain or loss)?

A: Official regulatory documents classify reported side effects by how frequently they occur. Changes in weight, such as weight gain or weight loss, are not listed among the documented common or uncommon adverse reactions in the official prescribing information.


Q: Does Omis affect a person's blood sugar levels?

A: Regulatory documents classify adverse reactions based on clinical trial data. Changes to blood sugar levels or blood glucose control are not included among the documented common, uncommon, or serious adverse reactions listed in the official safety profile for Omis.


Q: Can Omis cause skin sensitivity, particularly to sunlight?

A: Official documents list a rash as an uncommon reaction. Photosensitivity (increased skin sensitivity to light) is also documented as a possible, less common, skin-related adverse reaction.


Q: Does Omis interact with common over-the-counter pain relievers like ibuprofen or acetaminophen?

A: The official interaction statements focus on interactions with prescription drugs that affect specific enzyme pathways. Regulatory documents do not list a specific pharmacokinetic interaction with common over-the-counter pain relievers such as ibuprofen or acetaminophen.


Q: Is it safe to consume alcohol in moderation while using Omis?

A: Official prescribing information does not contain an explicit contraindication or warning against the consumption of alcohol while using Omis.


Q: Does Omis affect the effectiveness of hormonal birth control?

A: Studies have examined the co-administration of Omis with hormonal contraceptives. Official information indicates that these studies have not documented a clinically significant effect on the plasma concentrations or effectiveness of oral contraceptives.


Q: Is it generally advised to avoid driving or operating machinery while taking Omis?

A: Due to the possibility of side effects such as dizziness or somnolence (tiredness), which are listed as uncommon reactions, official information advises caution. The ability to drive or operate machinery may be affected if these symptoms occur.


Q: What is the general advice for managing a missed dose of Omis?

A: The official advice describes taking the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the advice indicates that the missed dose is skipped, and the regular schedule is followed.


Q: What is the factual difference between the brand name and any available generic versions of Omis?

A: Generic versions contain the identical active ingredient (Omeprazole) and must meet the same quality and strength standards as the brand name. Regulatory bodies require generics to demonstrate bioequivalence. The primary difference is often limited to the inactive ingredients used in the formulation.

How should Omis be stored and disposed of?

How to Store and Dispose of Omeprazole (Omis)

Storage and disposal requirements for Omeprazole are defined to protect the drug’s stability and prevent environmental contamination, according to official regulatory labeling.

️ Storage Conditions

Oral forms must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container, which must be tightly closed to provide mandatory protection from moisture. Omeprazole for injection, after reconstitution, has a defined, limited stability period and must be used within that time. All forms must be stored out of the reach of children.

️ Disposal Instructions

Official disposal rules prioritize using a drug take-back program or medicine collection point for unused or expired product. Regulatory guidance advises that Omeprazole must not be disposed of in wastewater or flushed down the toilet, protecting the environment from contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Omis found in:

A-Z Index: